Surreal illustration of hematopoietic stem cells infusion.

Day Zero Dilemmas: Navigating Adverse Reactions in Hematopoietic Stem Cell Transplants

Elliot Brynn monogram
Elliot Brynn in Health & Wellness October 2026 • 4 min read.

"A comprehensive guide to understanding, preventing, and managing adverse reactions during the critical first day of hematopoietic stem cell transplantation."


Hematopoietic stem cell transplantation (HSCT) represents a beacon of hope for individuals battling malignant and non-malignant hematological disorders. This complex procedure involves high doses of chemotherapy and/or radiotherapy, followed by the infusion of hematopoietic stem cells (HSCs). The goal? To rebuild a healthy blood and immune system, offering patients a chance at long-term remission or even a cure.

The journey through HSCT is divided into three distinct phases: pre-transplant, transplant (including the pivotal "day zero"), and post-transplant. Day zero marks the actual infusion of HSCs, a moment of both anticipation and potential risk. HSCs can be harvested from bone marrow (BM), peripheral blood (PB), or umbilical cord blood (UCB), each presenting unique advantages and challenges.

While HSCT offers remarkable possibilities, the infusion process on day zero is not without potential complications. Adverse reactions (ARs) can range from mild discomfort to severe, life-threatening events. Understanding these reactions, their causes, and effective management strategies is crucial for ensuring patient safety and optimizing treatment outcomes.

AI Search Multiple angles on this topic

The Impact of Day-Zero Reactions

Adverse reactions occurring on day zero of a hematopoietic stem cell transplant can create immediate clinical and emotional challenges. Their frequency and severity vary with the transplant context, patient condition, and reaction involved. Care therefore requires close observation and individualized clinical judgment rather than reliance on a single universal expectation.

Hematopoiesis and Transplant Foundations

Hematopoiesis is the process of blood cell formation, originating from hematopoietic stem cells located in the bone marrow of the femurs, pelvis, ribs, sternum, and other bones. These stem cells can differentiate into all types of mature blood cells, which explains their central role in hematopoietic stem cell transplantation. The hematopoietic system is broadly the body system involved in creating blood cells, while cell morphology may be examined using stains such as Wright's, May-Giemsa, or May-Grünwald-Giemsa; these foundational descriptions explain the biological basis of transplantation but do not by themselves define how every day-zero reaction should be managed.

Foundations of Blood-Cell Formation

The foundational concept behind hematopoietic stem cell transplantation is that blood cells arise through hematopoiesis. This process depends on stem cells capable of producing multiple mature blood-cell types. Understanding that relationship provides the biological framework for transplantation, although the supplied material does not establish a detailed historical timeline of the field.

Understanding Day Zero Adverse Reactions: What to Expect

Surreal illustration of hematopoietic stem cells infusion.

Adverse reactions during HSC infusion can manifest in various ways, impacting multiple organ systems. These reactions are influenced by several factors, including the characteristics of the infused product (volume, cell count, presence of cryoprotectants like DMSO) and the patient's individual health status. Nurses play a crucial role on Day Zero, being responsible for patient care activities before, during and after the HSC infusion. Their responsibilities are to prevent, identify, and intervene in possible complications related to the procedure.

Several factors can contribute to adverse reactions, categorized primarily into product-related and patient-related factors. Product-related factors include:

  • Volume of Infusion: Larger volumes can sometimes lead to fluid overload and related complications.
  • Cell Concentration: High concentrations of cells or granulocytes can trigger inflammatory responses.
  • DMSO Toxicity: Dimethyl sulfoxide (DMSO), a cryoprotectant used to preserve cells, can cause a range of reactions, from nausea to bradycardia.
  • ABO Incompatibility: Mismatches in ABO blood groups can lead to hemolytic reactions.
AI Search Multiple angles on this topic

Current Evidence and Clinical Interpretation

Interpretation of day-zero adverse reactions remains dependent on the clinical setting and the specific reaction observed. Available discussion should be integrated with the biological role of hematopoietic stem cells and the formation of mature blood cells. Because no study or review sources were supplied for this subsection, specific recent findings and research trends cannot be stated here.

Limits of Generalization

A central limitation in evaluating day-zero reactions is that general descriptions of the hematopoietic system do not explain every clinical event during transplantation. Hematopoietic stem cells have the capacity to differentiate into mature blood cells, but that biological fact alone does not identify the cause, severity, or outcome of an adverse reaction. Accordingly, conclusions about failures or competing interpretations require evidence beyond the material supplied here.

Comparing Clinical Contexts

Day-zero reactions may differ across transplant circumstances, but the supplied material does not provide comparative data between procedures, patient groups, or reaction types. What can be stated generally is that hematopoietic stem cells originate in bone marrow and contribute to the production of all mature blood-cell types. Without subsection-specific comparative studies, stronger claims about relative risks or outcomes would be speculative.

Understanding how these factors interact is essential for tailoring the transplantation process to minimize risks and enhance patient well-being. Patient-related factors include age, weight, pre-existing conditions, and overall clinical condition. Recognizing and addressing these variables can significantly improve patient outcomes during this critical phase of HSCT.

Empowering Patients and Professionals: A Collaborative Approach

Successfully navigating day zero of HSCT requires a collaborative effort between healthcare professionals and patients. By understanding the potential adverse reactions, implementing preventive strategies, and responding effectively to complications, we can significantly improve the safety and efficacy of this life-saving procedure. Further research and standardized protocols are essential to refine our approach and ensure the best possible outcomes for every patient undergoing hematopoietic stem cell transplantation.

AI Search Multiple angles on this topic

A Biological Framework for Judgment

The supplied material supports a basic synthesis: hematopoietic stem cells are bone-marrow-resident cells that can produce all mature blood-cell types. That biology is essential for understanding why transplant reactions matter, but it does not replace patient-specific assessment. Expert interpretation of a day-zero event therefore requires clinical information not included in the available sources.

Questions for Future Research

Future work could clarify how the biology of hematopoietic stem cells relates to the timing, mechanisms, and outcomes of adverse reactions during transplantation. The supplied sources establish the cell-forming role of hematopoiesis but do not identify emerging therapies, technologies, or research milestones. Specific forecasts would therefore go beyond the available evidence.

The Wider Transplant Context

Hematopoietic stem cell transplantation sits within the broader biological system responsible for creating blood cells. Because hematopoiesis involves stem cells that generate multiple mature cell types, disturbances around transplantation can have broad clinical relevance. The supplied material does not, however, provide evidence about healthcare access, institutional capacity, costs, or other systemic challenges.

Patient-Centered Implications

A day-zero adverse reaction can be a consequential experience for patients and families, particularly because it occurs at the beginning of a major treatment process. The biological importance of hematopoietic stem cells helps explain why transplant monitoring is significant. No patient narratives or outcome data were supplied, so the personal effects cannot be characterized more specifically.

What the infusion findings suggest

The reported events were not limited to products preserved with DMSO: reactions were also reported with noncryopreserved products. This means DMSO alone cannot account for every infusion-related event described in the evidence.[1]

The evidence links greater DMSO exposure with more frequent and severe toxicity, while also describing an attempt to reduce major cardiovascular effects by splitting the graft infusion. That approach was investigated as a possibility, not established here as a reliable prevention method.[2] [3]

How reaction rates compare across transplant settings

A small evaluation of washed peripheral blood stem cell components ended after severe infusion toxicity in one participant. It shows that removing DMSO after thawing did not eliminate the possibility of serious toxicity in that evaluation, but the small experience cannot establish how often this occurs more broadly.[2]

Sources

  1. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study. (pubmed.ncbi.nlm.nih.gov)
  2. Post-thaw removal of DMSO does not completely abrogate infusional toxicity or the need for pre-infusion histamine blockade. (pubmed.ncbi.nlm.nih.gov)
  3. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients | Haematologica (haematologica.org)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Hematopoietic Stem Cell Transplantation (HSCT) and why is it performed?

Hematopoietic Stem Cell Transplantation (HSCT) is a complex medical procedure used to treat both malignant and non-malignant hematological disorders. The primary goal of HSCT is to rebuild a patient's blood and immune system, offering the potential for long-term remission or even a cure. This is achieved by administering high doses of chemotherapy and/or radiotherapy, followed by the infusion of Hematopoietic Stem Cells (HSCs). The process is divided into three phases: pre-transplant, transplant (including day zero), and post-transplant. The infusion of HSCs on day zero is a critical point in the process.

2

What are the different sources of Hematopoietic Stem Cells (HSCs) used in HSCT?

Hematopoietic Stem Cells (HSCs), crucial for HSCT, can be sourced from several locations. The most common sources are bone marrow (BM), peripheral blood (PB), and umbilical cord blood (UCB). Each source presents its own unique advantages and challenges. The choice of source often depends on factors like patient condition, disease type, and availability.

3

What are the primary categories of factors that can lead to adverse reactions during the Hematopoietic Stem Cell (HSC) infusion on day zero?

Adverse reactions during the HSC infusion process on day zero are primarily caused by two types of factors: product-related and patient-related. Product-related factors involve characteristics of the infused product, such as the volume of infusion, cell concentration (especially granulocytes), the presence of Dimethyl Sulfoxide (DMSO) used as a cryoprotectant, and ABO blood group incompatibility. Patient-related factors include the patient's age, weight, pre-existing health conditions, and overall clinical status. Recognizing and addressing these factors is crucial for preventing and managing adverse reactions.

4

How does Dimethyl Sulfoxide (DMSO) contribute to adverse reactions during HSCT, and what symptoms might a patient experience?

Dimethyl Sulfoxide (DMSO) is a cryoprotectant used to preserve Hematopoietic Stem Cells (HSCs) before infusion. Although essential for cell preservation, DMSO can cause a range of adverse reactions. These can include nausea, changes in taste or smell, and even more severe complications like bradycardia (slowing of the heart rate). The reactions experienced depend on the concentration of DMSO and individual patient sensitivities. Nurses play a crucial role in monitoring for and managing these reactions.

5

What collaborative efforts are essential for ensuring a safe and effective day zero experience during Hematopoietic Stem Cell Transplantation (HSCT)?

Ensuring a safe and effective day zero during Hematopoietic Stem Cell Transplantation (HSCT) requires a collaborative approach between healthcare professionals and patients. Healthcare professionals, including nurses, must understand the potential adverse reactions, implement preventive strategies, and respond promptly to any complications. Patients, in turn, need to be informed about the procedure, potential risks, and their role in reporting any symptoms. Further research and standardized protocols are essential to refine this process and improve outcomes. Continuous monitoring and open communication are key elements of this collaboration.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.